Latest HER2/neu Stories
WORCESTER, Mass. and TORONTO, Nov. 13, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) today provided the following update on company initiatives. Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, is in late Phase II clinical development of a novel immunotherapeutic for breast cancer (AE37) that demonstrates promising trends in preventing relapse. The interim results of the large, controlled, randomized, and single blinded trial...
A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease. Xiaoting Zhang, PhD, and his colleagues have identified a specific estrogen receptor co-activator—known as MED1—as playing a central role in mediating tamoxifen resistance in human...
SAN ANTONIO, Oct. 16, 2012 /PRNewswire/ -- If Col. George Peoples has anything to say about it, pink ribbons will one day be obsolete and breast cancer will be a preventable disease. Peoples, chief of surgical oncology at San Antonio Military Medical Center (SAMMC) is the founder, director and principal investigator of the Cancer Vaccine Development Program (CVDP), an Army research network that this month is celebrating a few milestones toward its mission to prevent breast cancer....
The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to a study published October 5 in the Journal of the National Cancer Institute. Breast cancer is one of the most common causes of cancer deaths in the U.S. with approximately 39,520 women succumbing to the disease in 2011. HER2-postive breast cancer is known to be more aggressive and less responsive to treatments compared...
CAMBRIDGE, Mass., Oct. 2, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the presentation of Phase 1 safety and clinical results evaluating two potential new therapies with a novel target - ErbB3, a signaling receptor believed to be responsible for triggering tumor growth and resistance in a number of malignancies including breast, ovarian, gastric, esophageal and bladder cancers. The two studies were presented in poster sessions at the European...
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity. Breast...
The Vall d'Hebron Breast Cancer Unit, the Vall d'Hebron Institute of Oncology (VHIO) and SOLTI, an academic breast cancer research group are heading up a multi-center international study involving four Spanish and three North American research centers. The aim of the study is to investigate whether BKM120, a drug that inhibits the PI3K pathway (phosphatidylinositol-3-Kinase) can be an effective treatment against triple-negative breast cancer. At present it is known that breast cancer can...
CAMBRIDGE, Mass., Sept. 18, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research evaluating two novel compounds for advanced cancers, including breast, ovarian, gastric and bladder, will be presented at the ESMO 2012 Congress (European Society for Medical Oncology ), Sept. 28 - Oct. 2 in Vienna, Austria. The medicines are some of the first therapies developed using Merrimack's proprietary scientific approach - Network Biology - focusing...
WORCESTER, Mass. and TORONTO, Sept. 13, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) (www.generex.com), announced today presentation of early results from an efficacy study of an immunotherapeutic in triple negative breast cancer patients. The immunotherapeutic is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly owned subsidiary of Generex. The results will be presented on Friday, September 14, 2012 at the 2012 Breast Cancer...
A more-sensitive method to analyze protein interactions has uncovered a new way that cancer cells may use the cell-surface molecule HER3 to drive tumor progression following treatment with HER1 and HER2 inhibitors. The HER family of receptors has been linked to the development of a wide variety of human cancers. HER1 inhibitors such Iressa and HER2 inhibitors such as Herceptin are commonly used in the clinic for treatment of small cell lung carcinoma and breast cancer. A recent study...
